Q3 EPS Estimate for Telix Pharmaceuticals Reduced by Analyst

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Investment analysts at Wedbush lowered their Q3 2025 earnings per share (EPS) estimates for Telix Pharmaceuticals in a note issued to investors on Thursday, August 21st. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of $0.03 for the quarter, down from their prior estimate of $0.14. Wedbush currently has a “Outperform” rating and a $22.00 target price on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share. Wedbush also issued estimates for Telix Pharmaceuticals’ Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.07 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.12 EPS, FY2026 earnings at $0.37 EPS, Q1 2027 earnings at $0.14 EPS, Q2 2027 earnings at $0.15 EPS and FY2027 earnings at $0.65 EPS.

A number of other analysts have also commented on the company. William Blair reissued an “outperform” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. HC Wainwright started coverage on Telix Pharmaceuticals in a research report on Thursday, July 3rd. They set a “buy” rating and a $23.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $22.33.

Telix Pharmaceuticals Price Performance

Shares of TLX stock opened at $12.48 on Monday. The business’s 50-day moving average price is $14.47 and its 200-day moving average price is $16.25. Telix Pharmaceuticals has a 12 month low of $10.50 and a 12 month high of $30.36. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in TLX. Private Advisor Group LLC bought a new position in shares of Telix Pharmaceuticals during the first quarter worth about $170,000. IHT Wealth Management LLC bought a new stake in Telix Pharmaceuticals in the second quarter worth approximately $213,000. Blair William & Co. IL bought a new stake in Telix Pharmaceuticals in the second quarter worth approximately $217,000. Vanguard Personalized Indexing Management LLC bought a new stake in Telix Pharmaceuticals in the second quarter worth approximately $297,000. Finally, ABC Arbitrage SA bought a new stake in Telix Pharmaceuticals in the first quarter worth approximately $451,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.